

*The global commercial and technological leader for  
bio-pharma and clinical protein discovery,  
measurement, and interpretation*

# The Era of Proteomics is Here

March 2022



# Safe Harbor Statement

Certain information and statements in this presentation, particularly relating to the future of SomaLogic, our strategy, our product development plans, and the size and growth potential of the markets for our products and services, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act and other federal securities laws.

These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors.


Many factors could cause actual future events to differ materially from the forward-looking statements in this presentation, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.





# SomaLogic Investment Highlights



**Evolutionarily  
advanced  
technology  
platform**



**Heavily  
validated by  
customers and  
collaborators**



**Protein  
measurement and  
identification  
leader**



**Proteomics  
knowledge and  
applications  
leader**



**Significant  
technology and  
business  
trajectory**

**Uniquely Positioned to Harness the Power Of Proteomics**

# Key Achievements & Upcoming Milestones

Focused Successful Execution in 2021 Fuels Continued Growth in 2022 and Beyond

## FY 2021 - Achievements

Public Transition on Nasdaq (SLGC) / Capitalization Added \$630M to balance sheet via SPAC/PIPE	✓
Revenue Growth Original goal \$67M, achieved \$81.6M (46% y/y growth)	✓
Launch of 7,000 Protein Identification Platform	✓
Sales Team Growth 14 to 40 sales team personnel	✓
New Customer Growth 77 new customers	✓
Customer-Centric Business Model Shift	✓
Early Access Launch of Site-Of-Service Array Kits	✓

## FY 2022 - Milestones

Business Partnerships Announced NGS solution	✓
Revenue Growth Guidance of \$105-110M (reflecting 29-35% y/y growth)	
Completion of R&D on 10,000 Protein Identification Platform	
Sales Team Growth & Geo-Expansion in EMEA, APAC	
New Customer Growth	
Strategic M&A	
Full Commercial Launch Site-Of-Service Array Kits	
Development of Important New SomaSignal Tests	



# Groundbreaking Illumina Partnership

NGS BASED PROTEOMICS COMBINING SLGC AND ILMN TECHNOLOGIES



- **First major genomics-proteomics commercial partnership** (not simply platform enablement)
  - Multi-year partnership to enable and empower proteomics and multi-omics research worldwide
  - Leverages SomaLogic's leading proteomics platform and Illumina's global commercial infrastructure
- Specific to development of ***co-branded NGS-based deployed solution*** leveraging SomaLogic technology
  - Illumina will launch, market and sell into global installed base (>17K sites, 70% global NGS)
- ***Agreement is co-exclusive*** re: NGS-based solutions
  - **\$30M up-front + a ramp to \$25.9M minimum annual royalty** within 5 years of product launch
  - SOMAmer supply agreement, total royalty ramp payments and downstream dx fee opportunities for SomaLogic (not disclosed)



# Groundbreaking Illumina Partnership

NGS BASED PROTEOMICS COMBINING SLGC AND ILMN TECHNOLOGIES



- SomaLogic will deploy ***a variety of deployed protein ID and measurement solutions***:
  - NGS based (Illumina partnership)
  - Array-based (early access kits launched 2021)
  - “Next generation chip-based” (development underway)
- A total upside revenue agreement that ***accelerates SomaLogic’s strategy to be the comprehensive provider of proteomics solutions*** across life sciences tools and clinical diagnostics
  - Leveraging a uniquely flexible and accurate technology, balance sheet and overall platform.

# The Comprehensive Provider of Proteomics Solutions Serving a \$90B TAM

## Life Sciences Tools


PROTEIN ID AND MEASUREMENT –  
DEPLOYED AND SERVICE

## Clinical Products

HIGH PLEX PROTEIN DISEASE AND  
CONDITION DIAGNOSTICS (LICENSES,  
SALES, COMMERCIALIZATION,  
DEVELOPMENT)

## Data Services and Products

FOR ALL LST AND DX




SOMAmers

## Reagents

INTO A HOST OF OTHER PLATFORMS  
CURRENTLY USING Ab (LICENSES,  
SALES, ENABLEMENT, PARTNERSHIPS)




# Proteins Provide The Most Biologic And Disease Information



What has taken so long for proteins to be even more useful for biopharma and healthcare?

# Proteins Provide The Most Biologic And Disease Information


BUT WE ARE ONLY JUST NOW ABLE TO LEVERAGE IT




- The ability to measure a sufficient number of proteins
- Development of AI/ML to interpret and make use of the data
- High sensitivity, specificity and reproducibility

# SomaLogic Is Uniquely Positioned

**AT THE NEXUS OF PROTEOMICS  
NEEDS AND CAPABILITIES...**



**...TO CAPTURE A SIGNIFICANT SHARE OF THE RAPIDLY  
GROWING PROTEOMICS MARKET**





# SomaLogic's Evolutionarily Advanced Proteomics Platform



## TECHNOLOGY

### REAGENTS

Proprietary synthetic reagents  
~**700 patents** issued or pending

### CONTENT

Largest in the industry by **2X+**:  
**7,000 plex → 10,000 in 2022/2023**

### TECH SPECS

Industry leading sensitivity,  
specificity, CoVariance

Proprietary reagents with broad and deep measurement capabilities – highly sensitive, specific and reproducible.



## DATABASE

### SCALE

Database (**>450K samples**) with  
deepest proteome understanding

### DATA ACCESS

Unique biobank access and  
clinical partnerships

### REGULATORY RESOURCE

Unparalleled scale / throughput have created the world's largest proteomics database and knowledge resource.



## AI-POWERED BIOINFORMATICS STACK

### DATA

**>1B protein measurements**  
and **15M clinical data points**

### EXPERIENCE

**10+ years** of protein data  
bioinformatics experience

### AI/ML

Expertise and tools developed  
over a decade

ML and AI powered bioinformatics analytics and development that have created impactful clinical applications.



## SomaLogic's Platform Is Heavily Validated







# SomaLogic Life Sciences Tools


PROGRESS AND DEVELOPMENTS



# SomaLogic Is The Protein Measurement And Identification Leader



# Substantial Life Sciences Revenue Growth While Diversifying Customer Base



# Commercial Organization Buildout 2021 - 2022



# SomaLogic Life Sciences Tools Product Development and Deployment

CREATION OF A 10,000 PROTEIN MEASUREMENT AND OTHER PRODUCTS

- **ARRAY-BASED DISCOVERY KITS**

- Site-of-service **SomaScan array kits** delivered in early access in 2021
- General access anticipated late 2022

- **ARRAY PANEL PRODUCTS**

- Launched July 2021

- **10,000 PROTEIN SOMASCAN ARRAY ASSAY**

- Currently developing new aptamers (SOMAmer ligand reagents) at **500/quarter**
- Current protein supply agreements take us to **10,000 proteins measurable by EOY 2022** and commercialized early 2023
- Planning for **15,000-plex protein measurement capability in progress**





# SomaLogic Clinical Diagnostics


PROGRESS AND DEVELOPMENTS




# SomaLogic Is The Proteomics Knowledge And Applications Leader




# SomaSignal Test Availability



**2022**



*World's First Cancer Predisposition Tests in Development with Cancer Center of Excellence - Imperial College, London (30,000 samples)*



**2022 - 2024**

**Plus more than 50 additional health, wellness and disease prognosis tests in pipeline to develop, assess and validate**



# The Proteomics For Precision Medicine Initiative

THE WORLDS FIRST PROSPECTIVE CLINICAL STUDIES OF HIGH-PLEX PROTEOMICS DIAGNOSTICS




- Charter group of six premier US medical systems
- First six will evaluate CV Risk tests
  - Prescribing impact on T2 diabetics, others
- Trial enrollment initiated at four sites
- Initiative important for
  - New diagnostic platform market development
  - KOL relationships
  - Regulatory dossier data acquisition
- **The creation of a health system proteomics data consortium is under development**



# SomaLogic's Business Trajectory Potential Is Unique


AND POSITIONED TO CAPTURE MORE MARKET SHARE IN PROTEOMICS THAN OTHERS





# SomaLogic's Finances Past and Present: Persistence Pays

STRONG REVENUE TRAJECTORY AND BALANCE SHEET



# Our People

**Roy SMYTHE**  
Chief Executive Officer



**Melody HARRIS**  
President and COO



**Shaun BLAKEMAN**  
Chief Financial Officer



**Steve WILLIAMS**  
Chief Medical Officer



**Alan WILLIAMS**  
Chief Development Officer



**Todd JOHNSON**  
EVP of Business Development and Strategy



**Jason CLEVELAND**  
Chief Technology Officer



**Nebojsa JANJIC**  
Chief Scientific Officer



**Adam TAICH**  
Chief Business Officer




**Tracy HERVEY**  
EVP Research and Discovery Market



**Steve MERMELSTEIN**  
SVP of Corporate Strategy, Development and M&A





# The Era of Proteomics is Here